84680-54-6
84680-54-6 structure
- Name: Enalaprilat Dihydrate
- Chemical Name: enalaprilat dihydrate
- CAS Number: 84680-54-6
- Molecular Formula: C18H28N2O7
- Molecular Weight: 384.424
- Catalog: Biochemical Inhibitor Endocrinology & Hormones RAAS inhibitor
- Create Date: 2018-10-17 13:29:56
- Modify Date: 2025-08-26 18:07:52
-
Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 1.94 nM.Target: ACEEnalaprilat has high affinity for human endothelial ACE with IC50 of 1.94 nM in vitro binding assay by displacing a saturating concentration of [125I]351A, a radiolabeled lisinopril analogue from ACE binding sites, and shows bradykinin/angiotensin I selectivity ratio of 1.00 calculated from double displacement experiments [1]. Enalaprilat attenuates the IGF-I induced neonatal rat cardiac fibroblast growth (30% reduction) in a concentration-dependent fashion, with IC50 of 90 mM [2].Administration of Enalaprilat induces a significant reduction of MAP at 70 minutes compared with the placebo group during haemorrhagic shock in rats, and results in a 50% reduction of CO, a general tendency of EB extravasation which is significant in the kidney and lungs, and a significant increase in ileal EB extravasation (53%) [3].
| Name | enalaprilat dihydrate |
|---|---|
| Synonyms |
MFCD00941393
ENALAPRILAT DIHYDRATE 2-[N-(1-Carboxy-3-phenylpropyl)alanyl]-1-pyrrolidinecarboxylic acid dihydrate EINECS 278-459-3 1-Pyrrolidinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-, hydrate (1:2) |
| Description | Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 1.94 nM.Target: ACEEnalaprilat has high affinity for human endothelial ACE with IC50 of 1.94 nM in vitro binding assay by displacing a saturating concentration of [125I]351A, a radiolabeled lisinopril analogue from ACE binding sites, and shows bradykinin/angiotensin I selectivity ratio of 1.00 calculated from double displacement experiments [1]. Enalaprilat attenuates the IGF-I induced neonatal rat cardiac fibroblast growth (30% reduction) in a concentration-dependent fashion, with IC50 of 90 mM [2].Administration of Enalaprilat induces a significant reduction of MAP at 70 minutes compared with the placebo group during haemorrhagic shock in rats, and results in a 50% reduction of CO, a general tendency of EB extravasation which is significant in the kidney and lungs, and a significant increase in ileal EB extravasation (53%) [3]. |
|---|---|
| Related Catalog | |
| References |
| Boiling Point | 563.5ºC at 760 mmHg |
|---|---|
| Melting Point | 211-215°C |
| Molecular Formula | C18H28N2O7 |
| Molecular Weight | 384.424 |
| Flash Point | 294.6ºC |
| Exact Mass | 384.189636 |
| PSA | 125.40000 |
| LogP | 1.32630 |
| Index of Refraction | 1.579 |
| Storage condition | -20°C Freezer |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xi |
| Risk Phrases | R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . R36/37/38:Irritating to eyes, respiratory system and skin . |
| Safety Phrases | S22-S26-S36/37/39 |
| RIDADR | NONH for all modes of transport |
| RTECS | TW3590600 |